TABLE 2.
Multivariate logistic regression analyses
| A. | Joint logistic model of frequent exacerbators at baseline visit (≥2/year) | |||
|---|---|---|---|---|
| Variable | Odds ratio | 2.5% CI | 97.5% CI | p Value |
| Ex‐smoker | 2.32 | 1.26 | 4.42 | 0.008 |
| SABA | 2.33 | 1.16 | 4.77 | 0.019 |
| Sinusitis | 1.86 | 1.07 | 3.30 | 0.030 |
| Age of onset | 0.99 | 0.97 | 1.00 | 0.044 |
| OCS | 1.60 | 0.96 | 2.70 | 0.076 |
| FVC (% predicted) | 0.99 | 0.97 | 1.00 | 0.083 |
| Male | 0.65 | 0.38 | 1.10 | 0.109 |
| Eczema | 1.59 | 0.91 | 2.83 | 0.110 |
| Omalizumab | 0.59 | 0.30 | 1.18 | 0.131 |
| B. | Joint logistic model of persistent frequent exacerbators (≥2/year) | |||
|---|---|---|---|---|
| Odds ratio | 2.5% CI | 97.5% CI | p Value | |
| Eczema | 4.74 | 1.77 | 14.32 | 0.003 |
| SABA use | 4.70 | 1.96 | 11.76 | 0.001 |
| Mean ACQ5 | 1.66 | 1.16 | 2.44 | 0.007 |
| Total IgE | 1.00 | 1.00 | 1.00 | 0.079 |
| Exhaled NO | 0.98 | 0.97 | 1.00 | 0.010 |
| Male | 0.47 | 0.20 | 1.07 | 0.071 |
| Current smoker | 0.20 | 0.06 | 0.66 | 0.009 |
Abbreviations: ACQ5, Asthma Control Questionnaire (five questions); CI, confidence interval; FVC, forced vital capacity; IgE, immunoglobulin E; NO, nitric oxide; OCS, oral corticosteroids; SABA, short‐acting β agonist.